Apo AI Nanoparticles Delivered Post Myocardial Infarction Moderate Inflammation.-论文-万方医学网

第一作者： Adele L,Richart

第一单位： Baker Heart and Diabetes Institute, Melbourne, Australia (A.L.R., M.R., M.K., A.L.N., S.E.H., G.L.L., A.J.M., B.G.D., B.A.K.).

作者： Adele L,Richart ^[1] ; Medini,Reddy ^[1] ; Mina,Khalaji ^[1] ; Alaina L,Natoli ^[1] ; Sarah E,Heywood ^[1] ; Andrew L,Siebel ^[1] ; Graeme L,Lancaster ^[1] ; Andrew J,Murphy ^[1] ; Andrew L,Carey ^[1] ; Brian G,Drew ^[2] ; Svetlana A,Didichenko ^[2] ; Alexei V,Navdaev ^[3] ; Bronwyn A,Kingwell

作者单位： Baker Heart and Diabetes Institute, Melbourne, Australia (A.L.R., M.R., M.K., A.L.N., S.E.H., G.L.L., A.J.M., B.G.D., B.A.K.). ^[1] CSL Behring, Bern, Switzerland (S.A.D., A.V.N.). ^[2] Baker Heart and Diabetes Institute, Melbourne, Australia (A.L.R., M.R., M.K., A.L.N., S.E.H., G.L.L., A.J.M., B.G.D., B.A.K.).;Department of Physiology (B.A.K.), Monash University, Melbourne, Australia.;School of Medicine (B.A.K.), Monash University, Melbourne, Australia.;CSL Ltd, Bio21, Parkville, Australia (B.A.K.). ^[3]

主题词成年人(Adult);动物(Animals);消炎药(Anti-Inflammatory Agents);载脂蛋白A-Ⅰ(Apolipoprotein A-I);细胞, 培养的(Cells, Cultured);炎症趋化因子类(Chemokines);糖尿病, 2型(Diabetes Mellitus, Type 2);疾病模型, 动物(Disease Models, Animal);用药计划表(Drug Administration Schedule);人类(Humans);炎症(Inflammation);白细胞(Leukocytes);男(雄)性(Male);小鼠, 129系(Mice, 129 Strain);小鼠, 近交C57BL(Mice, Inbred C57BL);小鼠, 基因敲除(Mice, Knockout);中年人(Middle Aged);心肌梗死(Myocardial Infarction);纳米粒子(Nanoparticles);随机对照试验(主题)(Randomized Controlled Trials as Topic);清道夫受体, B类(Scavenger Receptors, Class B);肌钙蛋白I(Troponin I)

DOI 10.1161/CIRCRESAHA.120.316848

PMID 32951519

发布时间 2021-05-24

检索历史清除

Apo AI Nanoparticles Delivered Post Myocardial Infarction Moderate Inflammation.

Circulation research

相似文献

Circulation research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Apo AI Nanoparticles Delivered Post Myocardial Infarction Moderate Inflammation.

Circulation research

相似文献

Circulation research

相关期刊

检索历史清除